{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-101644","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2022-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.202346+00:00","generated_at":"2026-06-23T08:35:43.676108+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022","bullets":["Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.","Matthias Alder, formerly COO, appointed President and CEO and to a Board seat; receives $500k base salary, 50% target bonus, option for 60,900 shares, and 10,200 RSUs.","Richman entitled to $27,200/month consulting fee for 12 months, plus 329,400 option and 54,900 RSUs vesting on first anniversary.","Board adopted new non-employee director compensation policy: annual cash retainers ($40k board, $7.5k audit, etc.) plus initial option of 21,000 shares and annual award of 10,500 shares.","One-time off-cycle annual option of 10,500 shares granted to each non-employee director on Sept 20, 2022, vesting before next annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-101644","json":"https://secwatch.observer/filing/0001104659-22-101644.json","markdown":"https://secwatch.observer/filing/0001104659-22-101644.md","text":"https://secwatch.observer/filing/0001104659-22-101644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/tm2226134d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:35:43.676108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15889bd5d0","claim":"Eric Richman resigned as Chief Executive Officer at Gain Therapeutics, Inc..","evidence_excerpt":"Eric Richman informed the Board of Directors (the “Board”) of his intent to resign as Chief Executive Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"78fa25f8cd","claim":"Matthias Alder was appointed as Director at Gain Therapeutics, Inc..","evidence_excerpt":"Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fe861201f0","claim":"Matthias Alder was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..","evidence_excerpt":"Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}